1. Scrip's Cancer Chemotherapy Report, Scrip World Pharmaceutical News, PJB Publications Ltd, London (1996).
2. J. L. GREM, 5-Fluoropyrimidines, pp. 149–212 in Cancer Chemotherapy and Biotherapy 2nd ed. B.A. CHABNER, and D.L. LONG–Lippincott-Raven Publishers, Philadelphia (1996).
3. G. MILANO (eds.) and M. C. ETIENNE, Fluorinated pyrimidines pp. 289–300, in A Clinician's Guide to Chemotherapy Pharmacokinetics and Pharmacodynamics, L.B. GROCHOW and M. M. AMES, (eds.), Williams and Wilkins, Baltimore (1998).
4. C. J. ALLEGRA and J. L. GREM, Antimetabolites, pp. 432–451 in Cancer Principles & Practice of Oncology, 5th Eds., V. T. DEVITA and S. A. ROSENBERG, (eds.), Lippincott-Raven Publishers, Philadelphia (1997).
5. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile;Heggie;Cancer Res.,1987